MOR202
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glomerulonephritis, Membranous
Conditions
Glomerulonephritis, Membranous, antiPLA2R Positive
Trial Timeline
Oct 15, 2019 → Aug 2, 2022
NCT ID
NCT04145440About MOR202
MOR202 is a phase 1/2 stage product being developed by Biogen for Glomerulonephritis, Membranous. The current trial status is completed. This product is registered under clinical trial identifier NCT04145440. Target conditions include Glomerulonephritis, Membranous, antiPLA2R Positive.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04733040 | Phase 2 | Completed |
| NCT04145440 | Phase 1/2 | Completed |
Competing Products
8 competing products in Glomerulonephritis, Membranous
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| olmesartan medoxomil | Daiichi Sankyo | Phase 2 | 52 |
| infusion of ADR-001 (Mesenchymal stem cell) | Rohto Pharmaceutical | Phase 1 | 33 |
| Iptacopan | Novartis | Phase 2 | 52 |
| LNP023 | Novartis | Phase 2 | 52 |
| mycophenolate mofetil orally 1000 mg twice a day (BID) + prednisone 0,5 mg/kg orally on alternate days + intravenous (i.v.) methylprednisolone 1000 mg, total 9 | Roche | Phase 2/3 | 65 |
| ACE inhibitor + statin + Sirolimus (study drug)+ACE inhibitor + statin | Pfizer | Phase 2 | 51 |
| Ramipril | Sanofi | Phase 3 | 76 |
| MOR202 | Biogen | Phase 2 | 49 |